Federal jury rules Intel doesn't infringe two patents owned by VLSI Technology, in the second of three $1B+ trials over patents once owned by NXP Semiconductors
Context & Ripple Effects
This verdict is the middle act in VLSI Technology's campaign to monetize chip patents it acquired from NXP Semiconductors through serial Texas jury trials against Intel. A month earlier, Intel had suffered a crushing $2.18B jury verdict in the first trial, so a full defense here materially changes the scoreboard.
The series was far from over at this point: a third trial later produced a $948.8M award for VLSI, and a separate Delaware dispute — where Intel said VLSI sought more than $4B — was eventually settled out of court per a court filing ending that case. This no-infringement call is what kept the overall tally from being a sweep.
First-order effects
- VLSI walks away from the second of three planned $1B+ trials with nothing, cutting into expected returns on its NXP-derived portfolio after the opening $2.18B win.
- Intel caps its immediate liability in this round at legal costs alone, avoiding a second nine-to-ten-figure judgment stacked on top of the first.
Second-order effects
- A split record weakens VLSI's negotiating leverage: with one clear jury rejection on the books, the price Intel should rationally pay to settle the remaining claims — including the Delaware fight Intel valued above $4B — falls accordingly.
- Each verdict recalibrates how aggressively VLSI prices the third trial and any follow-on assertions, since damages expectations now hinge on a one-loss-one-win track record rather than an unbroken winning streak.
Third-order effects
- Jury outcomes on this portfolio proved fragile: a US appeals court later threw out the entire $2.18B win and ordered a retrial, underscoring that serial-litigation vehicles betting big sums on single Texas juries carry real reversal risk all the way up the appellate chain.
- If the pattern holds — huge jury swings, appellate unwinds, and partial settlements — the structural lesson for chipmakers like Intel is that defending against acquired-patent assertion campaigns is a multi-year war of attrition, not a single-verdict event.
The trend: Patent-assertion campaigns built on acquired semiconductor portfolios are becoming multi-trial wars of attrition, with individual billion-dollar jury verdicts increasingly subject to reversal or settlement rather than standing as final outcomes.